戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              S. maltophilia attaches to various mammalian cells, and
2                                              S. maltophilia has been isolated in association with nem
3                                              S. maltophilia is also a risk factor for lung exacerbati
4                                              S. maltophilia is highly resistant to most antibiotics,
5                                              S. maltophilia is increasingly observed in patient sputa
6                                              S. maltophilia-associated EE is a rare clinical conditio
7 ycline (MIN), and ceftazidime (CAZ) with 109 S. maltophilia bloodstream isolates.
8  developed and tested against a panel of 112 S. maltophilia isolates collected from diverse geographi
9 patients with > or =10 positive cultures (12 S. maltophilia cultures, 15 A. xylosoxidans cultures) ha
10  Sixty-one of 69 CF centers screened had 183 S. maltophilia culture-positive patients, and 46 centers
11              Analysis of a collection of 766 S. maltophilia isolates indicated that approximately 20%
12        Although patients with CF who acquire S. maltophilia have more advanced disease than those who
13            We compared patients who acquired S. maltophilia with those who did not, using survival an
14 resulted in amplification of a band from all S. maltophilia isolates and was uniformly negative for a
15 ver, as multidrug resistance is common among S. maltophilia isolates, treatment options for these inf
16 irB/D4] T4SS) that is highly conserved among S. maltophilia strains and, looking beyond the Stenotrop
17 ow that smlt0009 mutants already exist among S. maltophilia clinical isolates and have reduced suscep
18  aureus, A. xylosoxidans, D. acidovorans and S. maltophilia.
19  values for P. aeruginosa, A. baumannii, and S. maltophilia were 94.1%, 92.7%, and 95.5%, respectivel
20  values for P. aeruginosa, A. baumannii, and S. maltophilia were 99.5%, 99.2%, and 100%, respectively
21 n the optimal treatment of AmpC-E, CRAB, and S. maltophilia infections are limited.
22 ons about the treatment of AmpC-E, CRAB, and S. maltophilia infections.
23 E, AmpC-E, CRE, DTR P. aeruginosa, CRAB, and S. maltophilia.
24 E, AmpC-E, CRE, DTR-P. aeruginosa, CRAB, and S. maltophilia.
25 -pathogen interaction between C. elegans and S. maltophilia and established a new animal model with w
26 gnificantly differentially expressed between S. maltophilia JCMS and avirulent bacteria (Escherichia
27            While ocular infections caused by S. maltophilia are documented, endogenous endophthalmiti
28 ell as the inflammatory response elicited by S. maltophilia infection.
29               A diverse panel of 41 clinical S. maltophilia isolates collected through the SENTRY Ant
30 lly relevant antimicrobials against clinical S. maltophilia isolates nonsusceptible to levofloxacin a
31 genic bacteria also play a role in combating S. maltophilia JCMS.
32    Of 90 included patients, 8 (9%) developed S. maltophilia infection (pneumonia, n = 6; skin-soft ti
33 % of CF patients with moderate lung disease, S. maltophilia can be cultured from respiratory tract se
34     Little is known about factors that drive S. maltophilia infection.
35 nical microbiology laboratories were in fact S. maltophilia.
36 . aeruginosa, 14 for A. baumannii, and 2 for S. maltophilia Categorical agreement (CA) was assessed u
37 s (cASTs) and use CLSI breakpoints (BPs) for S. maltophilia.
38 boratories should use caution with cASTs for S. maltophilia, as a high rate of errors may be observed
39 mulative carbapenem use as a risk factor for S. maltophilia in leukemia patients.
40  S. maltophilia, those patients positive for S. maltophilia had the following baseline characteristic
41  had at least one sputum sample positive for S. maltophilia.
42 l cavity might identify patients at risk for S. maltophilia infection.
43 he oral microbiome as a potential source for S. maltophilia infection and highlight cumulative carbap
44 am plus aztreonam as combination therapy for S. maltophilia infections and confirm that aztreonam-lik
45    A putative alginate lyase (Smlt1473) from S. maltophilia was heterologously expressed in Escherich
46  P. aeruginosa elicited significantly higher S. maltophilia counts in bronchoalveolar lavages and lun
47                                     However, S. maltophilia JCMS is virulent to normally pathogen-res
48  tested their utility to accurately identify S. maltophilia directly from sputum.
49 col that can rapidly and accurately identify S. maltophilia isolates and which can be used for the di
50 e utility of the SS-PCR to directly identify S. maltophilia in sputum was examined.
51 inhibitors reverse ceftazidime resistance in S. maltophilia because, unlike clavulanic acid, they do
52 at Xps T2S likely plays an important role in S. maltophilia pathogenesis.
53 ergy transducer TonB, encoded by smlt0009 in S. maltophilia, confer ceftazidime resistance and smlt00
54 rates of the Xps type II secretion system in S. maltophilia strain K279a.
55 y represents the first examination of T2S in S. maltophilia, and the data obtained indicate that Xps
56 prove the penetration of antimicrobials into S. maltophilia by conjugating them with TonB substrates
57 ve P. aeruginosa, live E. aerogenes, or live S. maltophilia gave good recovery of cysts.
58                        We found that a local S. maltophilia isolate, JCMS, is more virulent than the
59 mits the therapeutic repertoire for managing S. maltophilia infections.
60             At the six centers with multiple S. maltophilia culture-positive patients and the seven c
61               Respiratory and nonrespiratory S. maltophilia isolates were highly immunostimulatory an
62 nt aminodeoxychorismate synthase activity of S. maltophilia PabB alone revealed that it is virtually
63                            No association of S. maltophilia infection with fecal relative abundance w
64  problem, the genetic and molecular basis of S. maltophilia virulence is quite minimally defined.
65 ere, we present the first documented case of S. maltophilia-associated EE in an immunocompetent adult
66 Foundation Registry, to assess the effect of S. maltophilia on survival.
67     To examine the molecular epidemiology of S. maltophilia and A. xylosoxidans in CF, isolates from
68                               The extents of S. maltophilia contamination of environmental sites freq
69 o dedicated pabA is evident in the genome of S. maltophilia, suggesting that another cellular amidotr
70  aeruginosa, the T4SS promoted the growth of S. maltophilia and reduced the numbers of heterologous b
71                            Identification of S. maltophilia can be problematic, and analysis of isola
72          Despite the lack of invasiveness of S. maltophilia, the immunostimulatory properties of this
73  strain K279a, the first clinical isolate of S. maltophilia to be sequenced, encodes a functional typ
74 typing can distinguish unique CF isolates of S. maltophilia and A. xylosoxidans, person-to-person tra
75 nd overall virulence of clinical isolates of S. maltophilia using the well-characterized opportunisti
76                       Eighty-two isolates of S. maltophilia were cultured from 67 different environme
77  evident among other respiratory isolates of S. maltophilia.
78                The source of the majority of S. maltophilia strains colonizing the respiratory tracts
79 pears to be important in the pathogenesis of S. maltophilia infection as less than 20% of TNFR1 null
80   Here, we investigated the pathogenicity of S. maltophilia alone and during polymicrobial infection
81 d cumulative antibiotic use as predictors of S. maltophilia infection in AML patients receiving remis
82          The immunostimulatory properties of S. maltophilia were studied in vitro by stimulating airw
83 automated in vitro susceptibility testing of S. maltophilia is challenging because commercial test sy
84  Colonization, persistence, and virulence of S. maltophilia were assessed in experimental respiratory
85 he SCV S. maltophilia isolates were the only S. maltophilia isolates in these cultures, and none were
86 ed with live P. aeruginosa, E. aerogenes, or S. maltophilia offer optimal recovery of Acanthamoeba.
87 olate, JCMS, is more virulent than the other S. maltophilia isolates (R551-3 and K279a) tested.
88 he primary outcome, microbiologically proven S. maltophilia infection, was analyzed using a time-vary
89 n all cases, the effect of the T4SS required S. maltophilia contact with its target.
90 maintain reliable activity against resistant S. maltophilia The role of minocycline in the treatment
91                                SXT-resistant S. maltophilia has been reported, but the mechanism of r
92                              Recovery of SCV S. maltophilia from the sputum of CF patients has implic
93                   Nutritional studies of SCV S. maltophilia have suggested auxotrophy in hemin, methi
94                                      The SCV S. maltophilia isolates were the only S. maltophilia iso
95 e to antibiotics may select for both the SCV S. maltophilia phenotype and SXT resistance by interfere
96 sis confirmed that once established, the SCV S. maltophilia strains persisted.
97  The phenotypic switch from wild-type to SCV S. maltophilia was reproducible in vitro by exposure to
98 ings of suspected small-colony-variant (SCV) S. maltophilia isolates from the sputa of five CF patien
99                   We have now confirmed that S. maltophilia also encodes a type IVA secretion system
100 c data from this study, we hypothesized that S. maltophilia strain ZL1 was able to convert E1 to amin
101     Furthermore, these results indicate that S. maltophilia may have clinical significance in respira
102      The results of this study indicate that S. maltophilia transiently colonizes the lung accompanie
103                    We recently reported that S. maltophilia strain K279a encodes the Xps type II secr
104 is of biofilms formed in vitro revealed that S. maltophilia formed well-integrated biofilms with P. a
105  Taken together, these findings suggest that S. maltophilia JCMS evades the pathogen resistance confe
106  mass spectral analysis further suggest that S. maltophilia PabB, like Escherichia coli PabB, binds t
107                                          The S. maltophilia isolates were weakly invasive, and low-le
108            Thus, we purified StmPr1 from the S. maltophilia strain K279a culture supernatant and eval
109 II) ions in the dinuclear active site of the S. maltophilia Class B3 MbetaL move away from each other
110  insight into the virulence potential of the S. maltophilia Xps type II secretion system and its StmP
111                             We show that the S. maltophilia complex is divided into 23 monophyletic l
112                                        Thus, S. maltophilia VirB/D4 T4SS appears to secrete multiple
113 . aeruginosa afford a significant benefit to S. maltophilia during polymicrobial infections.
114 vities exhibited by StmPr1 may contribute to S. maltophilia pathogenesis in the lung by inducing tiss
115 ycline in the treatment of infections due to S. maltophilia warrants further clinical investigation g
116 ne sequencing for identification and, unlike S. maltophilia, demonstrated susceptibility to most anti
117 997 who were older than 6 years of age, were S. maltophilia negative in the first year of enrollment,
118 aeruginosa, the hazard ratio associated with S. maltophilia detection was 0.89 (95% confidence interv
119 ng epidemiology indicates that patients with S. maltophilia have poorer diagnoses, its clinical signi
120 were bacteremic; and 7/8 (88%) patients with S. maltophilia infection had detectable levels of Stenot
121 mmercial susceptibility testing systems with S. maltophilia, with a focus on how to implement their u
122               Compared with patients without S. maltophilia, those patients positive for S. maltophil

 
Page Top